Kymera Q2 net loss narrows to $61.2M; KT-621 AD trial data accelerated to year-end 2026

Kymera Therapeutics, Inc.

Net loss of $61.2M vs $76.6M in Q2 2025; collaboration revenue of $65.0M from Gilead ($45M) and Sanofi ($20M) milestones.
Cash of $1.5B as of June 30, 2026, providing runway into 2029.
KT-621 Phase 2b AD trial enrollment completed ~6 months early; topline data now expected by year-end 2026 (vs mid-2027).
KT-579 Phase 1 healthy volunteer data expected 4Q26; lupus proof-of-concept trial planned.
Appointed Felix Baker as Chairman, Terence Rooney as CMO; Sanofi initiated KT-485 Phase 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.